26 results about "Vasoactive intestinal peptide" patented technology

The invention provides a stem cell exosome composition for treating erectile dysfunction and application thereof, the stem cell exosome composition comprises stem cell exosome and vasoactive intestinal peptide, and the amino acid sequence of the vasoactive intestinal peptide is shown as SEQ ID NO: 2. The amino acid structure of the vasoactive intestinal peptide is modified, so that the biological stability can be improved; the vasoactive intestinal peptide is combined with the adipose-derived mesenchymal stem cell exosome for use, so that the ED symptom can be relieved; the vasoactive intestinal peptide and the adipose tissue-derived stem cell exosome are combined for use, so that the expression level of cell factors can be adjusted, and the microenvironment of penis tissues can be improved.

The invention discloses a Lactobacillus paracasei metagen with a constipation relieving effect and application thereof, and belongs to the field of microorganisms. The lactobacillus paracasei CCFM1452 provided by the invention is relatively good in activity, and has certain acid and alkali resistance and adhesion. According to the present invention, with the application of the lactobacillus paracasei CCFM1452, the inflammation level in the colon tissue can be significantly reduced, the pathological damage of the colon tissue can be improved, the levels of the proinflammatory factor and the anti-inflammatory factor can be adjusted, the aquaporin expression level can be reduced, and the motilin MTL content in the colon tissue can be increased; the content of vasoactive intestinal peptide VIP in the colon tissue is reduced; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

Disclosed herein are stable liquid, suspension and dry powder compositions and methods for the delivery of stabilized biodegradable materials, including peptides and proteins, small molecules and methods for delivery in the treatment of pulmonary diseases. Specifically, the compositions include vasoactive intestinal peptides for pulmonary inhalation to treat respiratory and / or pulmonary diseases, including inflammation, acute and chronic lung injury and pulmonary edema.

The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and / or altered receptor binding profile with respect to unmodified VIP.

The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.

Disclosed herein are stable solution, suspension and dry powder compositions, and methods for delivering stabilized biodegradable substances, including peptides and proteins, small molecules, and methods for delivering the dry powders in the treatment of lung disease. In particular, the compositions comprise vasoactive intestinal peptide for pulmonary inhalation to treat respiratory disorders and / or diseases in the lung, including, inflammation, acute and chronic lung injury and pulmonary edema.

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

This invention provides a kit comprising: (1) a pharmaceutical composition containing a therapeutically effective amount of eugenol hydrochloride and a pharmaceutically acceptable carrier; and (2) a detection reagent for detecting vasoactive intestinal peptide (VIP) mRNA and / or protein. This invention reveals for the first time that eugenol hydrochloride (HH) has a highly effective therapeutic effect on specific Parkinson's disease patients characterized by abnormally elevated VIP levels. The pharmaceutical composition and kit of this invention can specifically reduce the expression of pro-inflammatory VIP, thereby precisely intervening in the VIP-mediated microglial-related neuroinflammatory pathway, thus significantly treating Parkinson's disease and providing a novel targeted treatment option for the clinical intervention of Parkinson's disease.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and / or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP / CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and / or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP), substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also relates to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the invention relates to restoration of transduction of signaling in cone PRs by ONS induced glutamate release. The methods of the invention, in some embodiments thereof, include priming of the retina choroid and optic nerve thereof to enhance the efficacy of cell transplantation therapy. The methods of the invention, in some embodiments thereof, also include identifying a subject prone to or suffering from a disease or condition associated with reduced OBF. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment where the patients are at pre-clinical stage of the disease. The OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.The present invention, in some embodiments thereof, relates to a method and / or device for treatment of dysregulated reduced blood (e.g. reduced ocular blood flow) and, more particularly, but not exclusively, to methods and / or devices for treatment retinal, choroidal and optic nerve disorders. Optionally, treatment may include application of an effective amount of ONS ophthalmic nerve stimulation alone and / or in combination with peri-ocular administration of substance Neuropeptides / Platelet Rich Plasma (N / PRP) and / or ascorbic acid as a sympatholytic agent

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for prompt treatment of cerebral and / or ocular strokes caused by acute dysregulated reduced cerebral blood flow (CBF) and / or ocular blood flow (OBF) by up regulation of trigeminovascular system (TVS), and trigeminal autonomic brain reflexes (TABRs) through stimulation of ophthalmic nerve. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated centrally by intravenous administration of pharmacological dose of ascorbic acid. The site of stimulation of ophthalmic nerve includes but not limited to nasal vestibule, nasal bridge, and forehead and upper eyelid. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for cerebral and ocular strokes. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in cerebral arteries, leptomeningeal collaterals and ophthalmic artery by the release of Vasoactive intestinal peptide (VIP), substance P and CGRP thereof increasing cerebral and / or OBF to the brain and the eye in subject's with acute dysregulated, reduced cerebral and / or OBF. The invention, in some embodiments thereof, is also relates to upregulation of TVS in a manner that is effective to induce acute development of leptomeningeal collateral circulation sufficient to ameliorate the ischemic effect of occluded cerebral artery, enhances successful recanalization, decreases the infarction volume and improves brain functional recovery without hemorrhagic transformation. In some embodiments TVS and ANS are also modulated in a manner that induce an acute increase in choroidal blood flow sufficient to ameliorate the ischemic effect of occluded artery until spontaneous recanalization of the occluded artery is accomplished. The invention is related to targeting the affected side via ipsilateral ONS without inducing intracerebral vascular steal phenomenon. The invention, in some embodiments thereof, is also relates to the methods for improving delivery of oxygen, glucose, anticoagulants, hormones, humoral mediators, growth factors and pharmacological agents to the targeted ischemic tissues of the brain, retina and optic nerve. The methods of the invention, when combined with r-tPA treatment and / or endovascular recanalization increases window time of treatment of stroke, enhance the efficacy of treatment and reduce its side effects. The methods of the invention, in some embodiments thereof, include priming of the brain, retina and / or optic nerve thereof to enhance the efficacy of cell transplantation therapy after exposure to stroke. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment. The cerebral / and or OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.

The invention discloses a lactobacillus rhamnosus metagen with a constipation relieving effect and application of the lactobacillus rhamnosus metagen, and belongs to the field of microorganisms. The lactobacillus rhamnosus CCFM1463 metagen provided by the invention can significantly reduce the inflammation level in colon tissue, improve pathological damage of colon tissue, reduce the expression level of proinflammatory factors, improve the expression level of anti-inflammatory factors, reduce the expression level of aquaporin, and increase the protein content of motilin (MTL), vasoactive intestinal peptide (VIP) and substance P (SP) in serum; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomy- opathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.

The present invention relates to methods and compositions for treating muscle diseases and disorders. The invention provides methods for treating muscle myopathies, including muscular dystrophy and cardiomyopathy, by administering stable, long-acting therapeutic agents for vasoactive intestinal peptides. These agents include one or more elastin-like peptides and can be administered at low doses.

A topical pharmaceutical blend for improving lubrication, moisturization, tissue regeneration, rejuvenation and blood flow of the vaginal area is provided. The pharmaceutical blends described herein may include vasoactive intestinal peptide (VIP) and vascular endothelial growth factor (VEGF). In some examples, the pharmaceutical blend may comprise both VIP and VEGF in less than about 1% by weight. The pharmaceutical blend can also include a lecithin carrier, and may be free of hormones.

There is provided compound for use in the treatment of vaginal laxity or a related disorder, which compound consists essentially of between 3 and 21 N-terminal amino acids of the peptide sequence: His-Ser-Asp-X4-X5-Phe-Thr-Asp-X9-Tyr-X11-Arg-X13-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys (SEQ ID No: 1) wherein: each of X4, X5, X9, X11 and / or X13 independently represent an amino acid selected from the group Ala, Val, Ile, Gly, Asn, Ser, Thr, Tyr and Leu; which peptide sequence is optionally coupled to the group Y or, in cases where the C-terminal amino acid is not Lys, to the group -Lys-Y; and Y represents one or more latanoprost molecules and / or one or more lipid, which lipid is selected from the group consisting of vitamin A, vitamin E, cholesterol and a fatty acid comprising one or more carboxylic acid groups, 1 to 50 carbons, and / or one or more cyclic rings, is linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted by between 1 to 10 -OH groups, or a derivative of any of these lipids; or a regioisomer, a stereoisomer, or a pharmaceutically-or cosmetically-acceptable salt thereof.

Artificial expression constructs are provided.SOLUTION: Artificial expression constructs are provided that selectively regulate gene expression in selected central nervous system cell types. Such artificial expression constructs can be used to selectively express synthetic genes or alter the expression of genes in inhibitory neocortical GABAergic neurons, including somatostatin GABAergic neurons, parvalmine GABAergic neurons, vasoactive intestinal peptide GABAergic neurons, Lamp5GABA GABAergic neurons, or in some instances astrocytes.SELECTED DRAWING: Figure 2-1

To provide artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations.SOLUTION: Artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic neurons generally; and / or GABAergic neuron cell types such as lysosomal associated membrane protein 5 (Lamp5) neurons; vasoactive intestinal polypeptide-expressing (Vip) neurons; somatostatin (Sst) neurons; and / or parvalbumin (Pvalb) neuron cell types. Certain artificial expression constructs additionally drive selective gene expression in Layer 4 and / or layer 5 intratelencephalic (IT) neurons, deep cerebellar nuclear neurons or cerebellar Purkinje cells.SELECTED DRAWING: Figure 1

The invention discloses a lactobacillus rhamnosus metagen with a constipation relieving effect and application of the lactobacillus rhamnosus metagen, and belongs to the field of microorganisms. The lactobacillus rhamnosus CCFM1039 metagen provided by the invention can obviously reduce the inflammation level in colon tissues, improve pathological damage of the colon tissues, reduce the expression of proinflammatory factors, improve the expression of anti-inflammatory factors, reduce the expression level of aquaporin and improve the protein content of motilin (MTL), vasoactive intestinal peptide (VIP) and substance P (SP) in serum; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group.

The invention discloses a circular RNA vaccine based on a vasoactive intestinal peptide delivery system and application of the circular RNA vaccine, and relates to the field of RNA vaccines. Comprising vasoactive intestinal peptide VIP serving as a delivery carrier and circular RNA for coding a respiratory syncytial virus RSVpreF antigen, and the vasoactive intestinal peptide VIP and the circular RNA form a compound through non-covalent linkage; the vasoactive intestinal peptide VIP is a VIP-EGFP-N fusion protein. According to the invention, the function of the VIP as a high-efficiency cell-penetrating peptide is explored and verified for the first time, and the VIP is combined with a circular RNA molecule of a coding RSV key antigen protein preF to construct a safe, stable and high-efficiency RSV vaccine, so that the technical bottlenecks of poor stability of the existing mRNA vaccine, complex and low-efficiency LNP delivery system, insufficient immunogenicity or poor safety of the traditional RSV vaccine and the like are solved.

The polypeptide feed is prepared from the following raw materials in percentage by mass: 35%-40% of a plant crude extract, 35%-45% of a protein source, 5%-8% of microbial flora and 15%-20% of a fermentation auxiliary material, wherein the plant extract is prepared from the following raw materials in percentage by mass: 50% of an astragalus membranaceus crude extract, 30% of a codonopsis pilosula crude extract and 20% of an angelica sinensis crude extract. The feed contains various plant and animal-derived amino acids, can supplement various nutrients in animal bodies, maintain amino acid balance, and is beneficial to enhancing protein fat absorption, promoting muscle and fat growth and improving meat quality and flavor, and meanwhile, the rich peptide contains various beneficial bacteria and free fatty acids, so that vasoactive intestinal peptide causes vasodilatation of mesentery, and the meat quality and flavor are improved. Protease and digestive enzymes are secreted in quantity, intestinal tract movement is enhanced, digestive absorption and anabolism of the body are enhanced, and therefore growth of the body is promoted.

The present invention provides a stem cell exosome composition for treating erectile dysfunction and its uses, including stem cell exosomes and vasoactive intestinal peptide, and the amino acid sequence of the vasoactive intestinal peptide is as shown in SEQ ID NO:2. The present invention modifies the amino acid structure of vasoactive intestinal peptide to improve its biological stability; the combined use of the vasoactive intestinal peptide and adipose mesenchymal stem cell exosomes can relieve ED symptoms; the combined use of the vasoactive intestinal peptide and adipose mesenchymal stem cell exosomes can regulate the expression level of cytokines and improve the penile tissue microenvironment.

The invention discloses a laxative composition and a preparation method and application thereof, and belongs to the technical field of veterinary medicine. The laxative composition of the invention comprises the following components: camellia seeds, tangerine peel, lotus flower, white ox gall, ox gall powder, propolis, liquorice and camellia oil. Animal experiments have shown that the laxative composition of the invention can significantly promote intestinal peristalsis and defecation of mice in a constipation model group, increase the levels of gastrin and vasoactive intestinal peptide in mouse serum and regulate intestinal microbial abundance, and the laxative composition can also significantly improve the constipation symptoms of sows. The laxative composition of the invention can effectively assist in lubricating the intestine and promoting defecation, has a significant therapeutic effect on constipation, is simple to prepare, has no toxic side effects, and has broad application prospects.

The invention discloses a Lactobacillus paracasei metagen with a constipation relieving effect and application thereof, and belongs to the field of microorganisms. The lactobacillus paracasei CCFM1451 provided by the invention is relatively good in activity, and has certain acid and alkali resistance and adhesion. According to the present invention, with the application of the lactobacillus paracasei CCFM1451, the inflammation level in the colon tissue can be significantly reduced, the pathological damage of the colon tissue can be improved, the levels of the proinflammatory factor and the anti-inflammatory factor can be adjusted, the aquaporin expression level can be reduced, and the motilin MTL content in the colon tissue can be increased; the content of vasoactive intestinal peptide VIP in the colon tissue is reduced; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

Presented herein are methods for stimulating neutrophil migration for bacterial clearance. The methods include stimulating IgG production by exposure to sensory neurotransmitters. The methods can be effective for the treatment of pneumonia. Also presented herein are methods for inhibiting eosinophilic infiltration and mast cell degranulation by inhibiting vasoactive intestinal peptide and / or Substance P release by sensory neurons. The methods can be effective for the treatment of allergy.